Abstract: Objective To investigate the current situation of clinical and imaging remission in patients with axial spondyloarthritis(axSpA) and analyze relevant impacted factors.Methods According to past treatment programs,ankylosing spondylitis disease activity scores based on C-reactive protein(CRP)(ASDAScrp)and Spondyloarthritis Research Consortium of Canada(SPARCC) scores,233 patientswith axSpA were divided into different groups respectively.Clinical data of each group were compared.Risk factors for clinical and imaging remission were analyzed by multivariate logistic regression analysis.Results Rate of clinical remission was 25.3% in patients with axSpA.Rate of imaging nonremission in clinical standard group(32.2%) was lower than that in clinical nonstandard group(56.3%,P<0.05).CRP in clinical standard group was lower than that in clinical nonstandard group,and ratio of patients receiving anti-tumor necrosis factor（TNF）-α treatment was higher than that in clinical non-standard group(P<0.05).ASDAScrp in imaging remission group was lower than that in imaging non-remission group,and ratio of patients receiving anti-TNF-α treatment was higher than that in imaging non-remission group(P<0.05).Rate of clinical standard and imaging remission in non-standard treatment group were lower than those in anti-TNF-α treatment group(P<0.05).Results of multivariate logistic regression analysis showed that CRP rise was risk factor for clinical non-remission in axSpA(P<0.001),while ASDAScrp rise was risk factor for imaging non-remission(P<0.05).Anti-TNF-α treatment was protective factor for both clinical and imaging remission(P<0.05).Conclusion Rate of clinical remission in axSpA is still low.CRP and ASDAScrp rise are risk factors for clinical and imaging non-remission in axSpA respectively,while anti-TNF-α treatment can promote clinical and imaging remission.

Key words: Axial spondyloarthritis, Clinical remission, Imaging remission, Tumor necrosis factor-α antagonists